Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group

Rachel E. Rau, Yunfeng Dai, Meenakshi Devidas, Karen R. Rabin, Patrick Zweidler-McKay, Anne Angiolillo, Reuven J. Schore, Michael J. Burke, Wanda L. Salzer, Nyla A. Heerema, Andrew J. Carroll, Naomi J. Winick, Stephen P. Hunger, Elizabeth A. Raetz, Mignon L. Loh, Brent L. Wood, Michael J. Borowitz

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The 5-year disease-free survival (DFS) of National Cancer Institute (NCI) high-risk (HR) B-lymphoblastic leukemia (B-ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation (EOC) MRD ≥0.01% is 39 ± 7%, warranting consideration of hematopoietic stem cell transplant (HSCT). However, the impact of EOC MRD in NCI standard-risk (SR) B-ALL patients using COG regimens is unknown. We found that SR patients with MRD ≥0.01% at both EOI and EOC have a 4-year DFS/overall survival (OS) of 72.9 ± 19.0%/91.7 ± 10.8% versus 90.7 ± 2.9%/95.5 ± 2.0% (p =.0019/.25) for those with EOI MRD ≥0.01% and EOC MRD <0.01%. These data suggest that routine use of HSCT may not be warranted in EOC MRD ≥0.01% SR patients.

Original languageEnglish (US)
Article numbere28929
JournalPediatric Blood and Cancer
Volume68
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • ALL
  • B-lymphoblastic leukemia
  • minimal residual disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this